« Previous | Next » | All Messages |  MDSM Message Board Home | recommend post |  Ignore Poster

MDSM News Research Update on Medistem Laboratories Issued by Beacon Equity Research

DALLAS--(BUSINESS WIRE)--A new research note has been issued on Medistem Laboratories, Inc. (OTCBB: MDSM) by Beacon Equity Research Senior Research Analyst, Lisa Springer, CFA.

The full report is available at http://www.beaconequityresearch.com

Anyone interested in receiving alerts regarding Medistem Laboratories, Inc. research should email members@beaconequityresearch.com with “MDSM” in the subject line.

In the report Ms. Springer writes, “With the initiation of clinical operations by its licensee in Costa Rica, Medistem is advancing its position as a leading provider of stem cell therapies on a fee-for-service basis. With the political pendulum swinging back in favor of stem cell research, Medistem’s experience and data gained abroad are expected to provide it an advantageous position when the regulatory climate in the U.S. eases. The Company expects its visibility within medical circles to increase as technical articles, supported by its patient data, are published in leading medical journals. At the same time, patents on discoveries such as the heart valve repair invention will solidify the Company’s competitive advantage and increase the value of its intellectual property portfolio.”

Beacon Equity Research Disclosure

The analysts contributing to this report do not hold any shares of Medistem Laboratories, Inc. (MDSM). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research (“Beacon”) certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. Beacon Research has been directly compensated eighteen thousand dollars for a one year enrollment in its program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.